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Abstract
 
Dendritic cells (DCs) play a central role in the immune system as they drive activation of T
lymphocytes by cognate interactions. However, as DCs express high levels of major histocom-
patibility complex class I, this intimate contact may also result in elimination of DCs by acti-
vated cytotoxic T lymphocytes (CTLs) and thereby limit induction of immunity. We show
here that immature DCs are indeed susceptible to CTL-induced killing, but become resistant
upon maturation with anti-CD40 or lipopolysaccharide. Protection is achieved by expression
of serine protease inhibitor (SPI)-6, a member of the serpin family that specifically inactivates
granzyme B and thereby blocks CTL-induced apoptosis. Anti-CD40 and LPS-induced SPI-6
expression is sustained for long periods of time, suggesting a role for SPI-6 in the longevity of
 
DCs. Importantly, T helper 1 cells, which mature DCs and boost CTL immunity, induce SPI-6
expression and subsequent DC resistance. In contrast, T helper 2 cells neither induce SPI-6 nor
convey protection, despite the fact that they trigger DC maturation with comparable efficiency.
Our data identify SPI-6 as a novel marker for DC function, which protects DCs against CTL-
induced apoptosis.
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Introduction
 
Dendritic cells (DCs)
 
*
 
 are highly specialized APCs that are
pivotal in the induction of immunity (1). In their immature
state, DCs can efficiently capture and process antigen, but
only through maturation these cells acquire the capacity to
prime naive T cells (1). DC maturation can be triggered by
a number of natural stimuli, including infectious agents, in-
flammatory cytokines, and ligation of the CD40 receptor.
This latter signal is delivered to the DCs through cognate
interaction with CD40L-expressing CD4
 
 
 
 Th cells, and
can be mimicked by agonistic anti-CD40 Ab (2–4). Matu-
ration converts DCs from antigen-scavengers into cells that
present a high density of peptide–MHC complexes and co-
stimulatory molecules (1). In addition, the maturation pro-
cess coincides with migration towards the lymphoid or-
gans, an event that involves expression of the chemokine
receptor CCR7 (5). When fully matured, DCs will stimu-
late naive CD8
 
 
 
 CTLs and provide these cells with their
“license to kill” (2–4, 6). This endows the CTLs with the
capacity to induce apoptosis in their target cells, which oc-
curs via two distinct mechanisms. The first cytotoxic
mechanism involves exocytosis of cytotoxic granules. Ap-
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Abbreviations used in this paper: 
 
c-FLIP, cellular Fas-associated death
domain–like IL-1
 
 
 
–converting enzyme-inhibitory protein; CMA, con-
canamycin A; DC, dendritic cell; EGFP, enhanced green fluorescent pro-
tein; Gr, granzyme; JAM, just another method; MAPK, mitogen-acti-
vated protein kinase; PI, protease inhibitor; SPI, serine PI. 
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optosis via this pathway is due to the combined actions of
the pore-forming molecule perforin and the cytotoxic pro-
tease granzyme (Gr)B (7, 8). After secretion by the CTLs,
this Gr binds to the mannose-6-phosphate receptor and en-
ters the target cell via receptor-mediated endocytosis (9,
10). Perforin then serves to release GrB from the endo-
somes into the cytoplasm of the target cell (10, 11). Once
delivered into the cytosol, GrB initiates the apoptotic sig-
naling cascade through cleavage of several substrates, in-
cluding Bid, inhibitor of caspase-activated DNase, caspase-3,
-7, and -8 (12–15). Although CTLs release other Grs, in
particular GrA, GrB is the key factor in the rapid induction
of DNA fragmentation and the absence of GrB greatly
hampers the capacity of a CTL to induce apoptosis via the
perforin pathway (8, 9). The second pathway used by a
CTL to kill its target cell is cross-linking of death receptors
on the target cell. This mainly involves CD95L (APO-1L,
FasL; references 16–18), which has been shown to induce a
caspase cascade that will lead to the destruction of the target
cell (19).
It is important to note that both these cytotoxic mecha-
nisms are induced rapidly upon activation of naive CTLs
(20, 21). Therefore, DCs that present the relevant MHC–
peptide complexes qualify as potential targets and are at risk
of being eliminated by the CTLs they have activated. Such
an event would seriously limit the capacity of DCs to
prime CTL immunity. Recently, it was proposed that DCs
are protected from premature CTL-mediated elimination
due to downregulation of cell surface expression of the
CCR7 homing receptor on activated CTLs (22, 23). This
would limit lymphoid localization of active CTLs and
thereby prevent a fatal interaction with DCs. However, re-
cent data suggest that this mechanism does not provide suf-
ficient protection, as injected populations of APCs were
cleared from the lymph nodes through a CTL-dependent
mechanism (B. Ludewig, University of Zurich, personal
communication; references 24 and 25). Furthermore, vi-
rus-induced acquired immune suppression in mice infected
with lymphocytic choriomeningitis virus was shown to in-
volve CTL-dependent elimination of APCs in peripheral
lymphoid organs (26). This indicates that DCs do become
exposed to the cytolytic machinery of activated CTLs in
vivo. Therefore, we performed a detailed analysis of the
consequences of interaction between DCs and effector
CTLs, using several defined DC cultures of murine and
human origin. We find that DCs effectively protect them-
selves against the actions of CTLs by expression of the
GrB-inhibitor serine protease inhibitor (SPI)-6/PI-9, pro-
vided that they receive the appropriate maturation signals.
 
Materials and Methods
 
Mice, Cell Lines, and Reagents.
 
Female C57BL/6Kh (B6,
H-2b) and DO11.10 TCR transgenic mice (provided by Dr. M.
Wauben, Utrecht University, Utrecht, Netherlands) were kept at
the LUMC animal facility and used at 6–10 wk of age in accor-
dance with national legislation and under supervision of the ani-
mal experimental committee of the University of Leiden. OVA-
 
specific Th1 and Th2 cells were obtained from DO11.10 TCR
transgenic mice. Th1 cells were generated as described previously
(27, 28). Th2 cells were generated from D011.10 mice in a simi-
lar fashion as Th1 cells except that the medium was supplemented
with 20 ng/ml IL-4 (Peprotech), 10 
 
 
 
g/ml anti–IL-12 (C17.8, a
gift from Dr. A. van Halteren, LUMC), and 10 
 
 
 
g/ml anti–IFN-
 
 
 
(XMG1.2) instead of recombinant IL-12 and anti-IL4.D1, a
long-term growth factor–dependent murine DC cell line was a
gift from Dr. P. Ricciardi-Castagnoli and cultured as described
previously (29). Primary bone marrow DCs were generated by
culturing bone marrow isolates from C57BL/6Kh mice (30) in
D1 culture medium (29). These bone marrow DC cultures are
standardly 
 
 
 
80% CD11c
 
 
 
 of which 
 
 
 
10% is mature as measured
by B7-2 expression. Spleen cell DCs were isolated directly from
homogenized spleen (C57BL6/Kh) by cell sorting using anti-
CD11c/FITC and anti-B7-2/PE to determine the maturation
status. Human monocyte–derived DCs were generated using a
standard protocol with IL-4 and GM-CSF as described previously
(31). The E1B-specific CTL clone 100B6 was cultured routinely
as described previously (32). Retroviral transduction of D1 cells
was performed as described with an LZRS-based vector encod-
ing either enhanced green fluorescent protein (EGFP) or vsv-
tagged SPI-6 plus EGFP (33). Tranduced cells were sorted twice
on the basis of EGFP expression. The anti-CD40 (FGK45) anti-
body was a gift from Dr. A. Rolink (Basel Institute for Immunol-
ogy, Basel, Switzerland) and used at 50 
 
 
 
g/ml. LPS of 
 
Escherichia
coli 
 
was obtained from Difco Laboratories and used at 10 
 
 
 
g/ml
for murine DCs and at 1 
 
 
 
g/ml for human DCs. Murine and hu-
man leucine zipper CD40L was a gift of Dr. M. Kubin (Immu-
nex) and used at 1 
 
 
 
g/ml. IL-10 was added to the D1 cultures at
50 ng/ml while IFN-
 
 
 
 was used at 10 IU/ml. CD40L blocking
experiments were performed with 50 
 
 
 
g/ml moAb MR-1, IL-
10 was blocked using 5 
 
 
 
g/ml moAb JES5-2A5 (BD PharMin-
gen), and IL-4 was blocked using 10 
 
 
 
g/ml of the moAb 11B11
(a gift from Dr. A van Halteren).
 
Cell Surface Staining, Western Blot Analysis, and ELISA.
 
FACS
 
®
 
 analysis for B7-2 was performed with GL-1 (BD Phar-
Mingen). Western blot analysis was performed with polyclonal
rabbit anti–mitogen-activated protein kinase (MAPK) as a control
antibody (34) or with MoAb17 generated against PI-9, which is
specific for PI-9 (human) (35) and efficiently crossreacts with
(murine) SPI-6 (Fig. 2 b). Western blot analysis were developed
using HRP-coupled secondary antibodies and ECL. The murine
IL-12(p40) and human IL-12(p70) ELISA were performed as de-
scribed previously (27, 31). The murine IL-10 ELISA was per-
formed using the ELISA kit from BD PharMingen.
 
PCR and Northern Blot Analysis.
 
PCR of a 741-bp fragment
of SPI-6 (from 737–1,477) was performed using GCTCCCA-
GATGAGGGTGT as forward and TCTCTCTAGCTCCAT-
TAT as reverse primer. Resulting PCR product was sequenced
and compared with the published sequence (36) to certify the
identity of the product. A GAPDH control PCR (fragment
length 232 bp, 384–615) was performed with GAGC-
CAACGGGTCATCATCT and GAGGGGCCATCCACAGT-
CTT as primers. Northern blot analysis was performed using
10 
 
 
 
g per lane of total RNA from either immature or FGK45-
matured D1 cells. A [
 
32
 
P]-labeled probe was generated with
random priming using the complete SPI-6 coding region as a
template.
 
Just Another Method.
 
The just another medthod (JAM) assay
was performed essentially as described previously (32, 37) and de-
tects DNA fragmentation, a hallmark in the induction of apopto-
sis (38). In short, D1 cells were labeled with 1 
 
 
 
Ci of [
 
3
 
H]thymi- 
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dine for 3 d during which they were treated with LPS for 24 h or
FGK45 for 48 h, which both result in full maturation. Assays
were performed with 1,000 target cells (1,000–2,000 cpm) per
well and in the presence of cold thymidine (1.5 
 
 
 
M) for 6 h. Tar-
gets were loaded with peptide at 1 
 
 
 
g/ml just before the assay. In
most experiments the E1B-specific CTL clone was used as effec-
tor population at the indicated E:T ratios. In a separate set of ex-
periments we used in vivo–activated CTLs, which were obtained
essentially as described previously (39). In short, splenocytes iso-
lated from mice that were immunized 10 d earlier with a temper-
ature-sensitive mutant of Adenovirus type 5 (Ad5
 
ts
 
125) were re-
stimulated with 10% irradiated tumor cells (XhoC3) that express
the Adenovirus E1A and E1B proteins. Restimulation was per-
formed for 6 d after which the cultures were applied to a Ficoll
gradient to isolate living cells. In this fashion, bulk CTL cultures
were obtained that are specific for the E1B epitope and these
were used at the indicated E:T ratios. Assays were left for 6 h at
37
 
 
 
C and all assays were performed in six-plo to minimize the
variation. Where indicated the E1B-specific CTL clone was pre-
incubated with concanamycin A (CMA; Sigma-Aldrich) (40) for
2 h at 30 nM. CMA was present throughout the assay.
 
CaspaTag Cytotoxicity Assay.
 
10
 
5
 
 immature or FGK-matured
(48 h) D1 cells where incubated for 3.5 h with the E1B-specific
CTL clone at an E:T ratio of 3 in the absence or presence of
E1B-peptide (1 
 
 
 
g/ml). After this initial incubation, CTLs were
stained for 10 min at 37
 
 
 
C with anti-CD8
 
 
 
-APC (Ly-2; BD
PharMingen). A further incubation at 37
 
 
 
C for 1 h was per-
formed in the presence of CaspaTag (FAM-VAD-fmk; Intergen)
according to the manufacturer’s indications. CaspaTag irrevers-
ibly binds to active caspases and was used to detect the caspase ac-
tivity in the target cell on a FACScan™ (Becton Dickinson) by
gating out the CD8
 
 
 
 
 
 CTLs and measuring the fluorensence in-
tensity of the CaspaTag (fl-1) in the target cells.
 
Results
 
Mature DCs Resist CTL-induced Apoptosis.
 
The murine
D1 cell line displays a stable phenotype typical for imma-
ture DCs unless it receives an activation signal through ag-
onistic anti-CD40 Ab, LPS, or Th cells (27, 29). This trig-
ger results in fully matured D1 cells that are highly capable
of CTL priming (27). To directly analyze the sensitivity of
DCs for CTL-mediated killing, we measured the efficacy
of a CTL clone to induce antigen-dependent apoptosis in
both immature and mature D1 cells. Immature D1 cells,
exogenously loaded with the relevant antigen, were highly
susceptible to CTL-induced DNA fragmentation as mea-
sured in a JAM assay (37, 38) (Fig. 1 a). This cytotoxicity
was largely perforin-dependent as it was blocked by CMA
(Fig. 1 b), a substance that specifically prevents perforin-
dependent cytotoxicity (40). Interestingly, maturation of D1
with anti-CD40 Ab or LPS prevented CTL-induced apop-
tosis (Fig. 1 a). Notably, even though anti-CD40 or LPS
treatment resulted in maturation of a large fraction of the
D1 cells (70–80%), a small population remained immature.
This most likely explains the residual killing that is detected
in our cytotoxicity assay when using anti-CD40 or LPS-
matured D1 cells as targets (Fig. 1 a). Insensitivity to CTL-
mediated killing was not due to the lack of recognition by
the CTLs, as both anti-CD40 and LPS-matured D1 cells
Figure 1. Sensitivity of D1 cells for CTL-induced apop-
tosis. (a) D1 cells were labeled with [3H]thymidine and ex-
ogenously loaded with Adenovirus E1B peptide. Labeled
cells were either left untreated (immature, circles), treated
with LPS for 24 h (triangles), or anti-CD40 for 48 h
(FGK45, squares) and subsequently incubated at different
E:T ratios with E1B-specific CTL clone for 6 h. (b) D1
cells were treated as indicated under a, and incubated at
different E:T ratios with E1B-specific CTL clone for 6 h in
the absence (white) or presence (black) of 30 nM CMA.
(c) Splenocytes from C57BL/6 mice immunized with
Adenovirus type 5 were once restimulated in vitro and
subsequently used as effectors at the indicated E:T ratios.
D1 cells (circles) or anti-CD40-matured D1 cells (squares)
were labeled with [3H]thymidine and exogenously loaded
with the E1B peptide. The specific amount of thymidine
released in a, b, and c, which is a measure for CTL-
induced apoptosis, is then calculated and given as a per-
centage of the maximal releasable amount. (d). Immature
or anti-CD40–matured D1 cells were incubated with the
E1B-specific CTL clone in the absence (light gray) or pres-
ence (dark gray) of the E1B peptide and analyzed for their
caspase activity with the use of CaspaTag. The percentage
of cells that stained positive for caspase activity is given. 
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express very high levels of MHC class I (27, 29) and effi-
ciently induce CTL activation as measured by the secretion
of IFN-
 
 
 
 (data not shown). The observed difference was
also not restricted to this particular CTL clone, as it was de-
tected with a separate clone that contains a distinct peptide
specificity (data not shown). Moreover, polyclonal CTL
cultures, obtained by restimulation of splenocytes from Ad-
enovirus-infected C57BL/6 mice, efficiently induced
DNA fragmentation of D1 cells, but failed to kill anti-
CD40–matured D1 cells (Fig. 1 c). This indicates that the
lack of CTL-induced DNA fragmentation in anti-CD40–
matured D1 cells is a general feature. Although DNA frag-
mentation is a very reliable marker of apoptosis, it is a
rather late event that can be prevented through interven-
tion with the apoptosis signaling cascade at several different
points. Therefore, we analyzed one of the most proximal
events in perforin-dependent apoptosis, which is the acti-
vation of caspases. Upon incubation with the E1B-specific
CTL clone, we observed that a proportion of the immature
D1 cells displayed caspase activity (Fig. 1 d). This caspase
activity was dependent on the presence of the E1B peptide
and was thus induced by the CTLs in an epitope-speci-
fic manner (Fig. 1 d). More importantly, CTL-induced
caspase activation was not observed in D1 cells that had
been matured with anti-CD40 (Fig. 1 d). This indicates
that inhibition of CTL-induced apoptosis occurs already at
a proximal point in the cascade of events that lead to target
cell apoptosis and implies that a powerful mechanism must
be in place to protect mature DCs against elimination by
activated CTLs.
 
The Antiapoptotic Protein SPI-6 Is Induced during DC Mat-
uration.
 
Perforin-dependent target cell apoptosis is mainly
due to the activity of the serine protease GrB (7, 8). There-
fore, we investigated whether DCs resistance involves
blockade of this protease. In this respect, it is interesting to
note that CTLs were previously reported to express a GrB
inhibitor, which was suggested to provide CTLs with a
protective mechanism against their own lytic machinery
(36, 41). This inhibitor, which is called PI-9 in human and
SPI-6 in mouse, belongs to the SPI (serpin) family and spe-
cifically binds and inactivates GrB in vitro
 
 
 
(36, 41, 42). To
directly determine whether this GrB-inhibitory serpin is
expressed in DCs and is related to their resistance from
CTL-mediated apoptosis, we analyzed the expression levels
of SPI-6 in D1 cells. Both semiquantitative PCR and
Northern blot analysis revealed very low expression of SPI-6
mRNA in immature D1 cells (Fig. 2 a). In accordance,
only low levels of SPI-6 protein could be detected (Fig. 2
b). Importantly, strong induction of SPI-6 mRNA was ob-
served mainly during CD40-induced maturation (Fig. 2 a),
in line with a rapid and strong increase of SPI-6 at the pro-
tein level (Fig. 2 b). Similarly, LPS-induced maturation re-
sulted in increased levels of SPI-6 protein (Fig. 2 b).
As the D1 cells represent a long-term cell line, we veri-
fied our observations using primary DCs. Immature
CD11c
 
 
 
 DCs, generated from murine bone marrow, were
found to express little SPI-6 (Fig. 3 b). Treatment with
CD40L resulted in maturation of these DCs (Fig. 3 a) and,
concomitantly, in a marked increase in SPI-6 expression
(Fig. 3 b). As was found for D1 cells, bone marrow DCs
were highly sensitive to CTL-induced apoptosis in their
immature state, but insensitive after maturation (Fig. 3 c).
SPI-6 induction is not confined to DC maturation
 
 
 
in
vitro, as two serial injections of anti-CD40 into mice re-
sulted in the in vivo induction of SPI-6 mRNA in
CD11c
 
 
 
 spleen cell DCs (Fig. 3 d). Furthermore, regula-
tion of serpin expression is conserved between mouse and
man. Immature human monocyte–derived DCs were
found to express low basal levels of the human homologue
of SPI-6, PI-9, whereas CD40-dependent maturation of
these DCs resulted in greatly increased PI-9 expression
(Fig. 3 e). Taken together our observations demonstrate
the generality of this feature for both murine and human
DCs and point at a role for SPI-6/PI-9 in the protection of
mature DCs against elimination by CTLs.
 
Overexpression of SPI-6 Conveys Resistance to CTL-induced
Apoptosis, but Is not a Consequence of DC Maturation persé.
 
To address the question whether there is indeed a causal re-
lation between SPI-6/PI-9 expression in mature DCs and
their insensitivity to CTL-induced apoptosis, we trans-
duced the D1 cells with a retrovirus encoding SPI-6. In
agreement with previous observations by Gasperi et al
 
.
 
(43), we found that retroviral gene-transduction does not
change the immature state of D1 cells (data not shown). As
Figure 2. SPI-6 is expressed in D1 cells. (a) D1 cells were treated with
Lz-CD40L, FGK45, or LPS as indicated and SPI-6 expression was deter-
mined with semiquantitative rtPCR or Northern blot analysis (two tran-
scripts). Top panels represent SPI-6, while bottom panels represent a con-
trol rtPCR/Northern for GAPDH. (b) Cells were treated as under (a) and
tested for the protein expression of SPI-6 on Western blot (top). Lysates
from equal numbers of cells were applied on SDS-PAGE (0.5   106 cells)
and equal protein loading was further checked by ponceau S staining. In
addition, an antibody against MAPK was used as a control (bottom). A mu-
rine tumor cell line transduced with a retrovirus encoding SPI-6 and the
non-transduced parental cell line (MBL2FasFLIP; MFF) were used as con-
trols to ensure that the anti-PI-9 mAb specifically cross-reacted with SPI-6. 
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a result, we obtained immature D1 cells overexpressing
SPI-6 at levels comparable to that observed in anti-CD40–
matured D1 cells (Fig
 
.
 
 3 f). These immature SPI-6 gene-
transduced D1 cells were highly resistant to CTL-induced
apoptosis (Fig. 3 f). This indicates that SPI-6 expression as
observed in matured DC suffices to protect these cells from
CTL attack and, therefore, can fully account for this resis-
tant phenotype.
Maturation of DCs during the priming of T cell immune
responses in vivo
 
 
 
can occur via cognate interaction with
Th cells (2–4). Classically, these Th cells can be divided
into subsets on the basis of their cytokine profile (44). Th1
cells are IFN-
 
 
 
–secreting cells that foster development of
CTLs, while Th2 cells secrete IL-4 and IL-10 and skew the
immune system towards humoral responses (44). This
functional difference between Th subsets prompted us to
analyze their effects on SPI-6 expression in DCs. We made
use of TCR transgenic CD4
 
 
 
 T cells derived from the
 
DO10.11 mouse strain, which are directed against the
I-A
 
b
 
–restricted OVA epitope 323–339 (ISQAVHAA-
HAEINEAGR). These CD4
 
 
 
 T cells can develop into
Th1 or Th2 type cells by in vitro culturing in the presence
of antigen in combination with respectively IL-12 and
anti–IL-4 or IL-4, anti–IL-12, and anti–IFN-
 
 
 
 
 
(29). Incu-
bation of Th1 or Th2 cells with D1 cells (at a ratio of 1:20)
resulted in maturation in an antigen-dependent fashion
(Fig. 4 a). As was reported before (29), only Th1 cells had
the capacity to induce IL-12 secretion by DCs, a cytokine
that feeds back into Th1 development and reportedly facil-
itates CTL formation (45). Importantly, also the expression
of SPI-6 was only induced by Th1 cells, while Th2 cells re-
mained without effect (Fig. 4 b). Controls reveal that the
SPI-6 expression detected in this experiment was derived
from the D1 cells and not the Th1 cells (Fig. 4 b).
Interestingly, the immune-regulatory cytokine IL-10 has
previously been reported to reduce IL-12 secretion by DCs
Figure 3. SPI-6 is expressed in primary DCs and pre-
vents cytotoxicity. Primary bone marrow DCs were either
left untreated or treated for 48 h with Lz-CD40L and
tested for (a) B7-2 expression by FACS® analysis, (b) SPI-6
expression using Western blot analysis, and (c) CTL sensi-
tivity as described in Fig. 1 a. (d) Spleen cell DCs were iso-
lated by FACS® sorting using CD11c and B7-2 expression
as markers. Cells were isolated either from untreated mice
(sorted for immature DC, B7-low) or from FGK45-
injected mice (sorted for mature DCs, B7-high) and SPI-6
as well as GAPDH expression was determined directly by
rtPCR. (e) Primary human monocyte–derived DCs were
treated with Lz-CD40L or LPS for 24 h and tested for PI-9
expression (i.e., the human homologue of SPI-6) by West-
ern blot analysis. In all cases lysates from equal numbers of
cells were applied on SDS-PAGE (0.5   106 cells) and
equal protein loading was further checked by ponceau S
staining and control Western for MAPK (bottom). (f) D1
cells transduced with control retrovirus (white squares) or
SPI-6-encoding retrovirus (black squares) were tested for
SPI-6 expression by Western blot (inset) and CTL sensitiv-
ity by DNA fragmentation. 
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Figure 4. Th1 induces, while Th2 and
IL-10 block SPI-6 induction in D1. (a) 5  
104 OVA-specific Th1 and Th2 were incu-
bated with 106 D1 cells for 48 h. Maturation
of OVA peptide–loaded D1 cells was mea-
sured by B7-2 expression. (b–d) 106 D1 cells
were incubated with 5   104 Th1 or Th2
cells, peptide, anti-CD40L, and anti–IL-10
as indicated and tested for IL-12p40 secre-
tion by ELISA and SPI-6 expression by
Western blotting after 24 h. Lysates from
equivalent numbers of cells were applied on
SDS-PAGE (0.5   106 cells). Equal protein
loading was confirmed by ponceau S stain-
ing as well as by a control Western for
MAPK (bottom). Please note that D1 cells
were incubated with Th cells at a ratio of
20:1, resulting in a 20-fold lower protein
content in the samples that contained Th
cells only (right lanes). (e) Anti-CD40
(FGK) or Th1-induced SPI-6 expression in
D1 cells was determined after 48 h in the
absence or presence of IL-10 (left). The
right panel represents SPI-6 expression in
D1 cells after incubation with Th2 cells in the
presence or absence of IFN- , anti–IL-10,
and anti–IL-4 as indicated. As a control the
Th1-induced SPI-6 expression is shown on
the far right. (f) DNA fragmentation of
Th1- (circles) or Th2 (triangles)-matured
D1 cells (E1B-peptide loaded) was tested
with the E1B-specific CTL clone for 6 h as
described in the legend to Fig. 1 a. 
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(29) and is mainly secreted by Th2 cells. Also our Th2 cells
produce large quantities of this cytokine (244.2 ng/ml per
million cells), while our Th1 cells produce relatively little
IL-10 when activated by DCs (4.6 ng/ml per million cells).
Therefore, we analyzed whether IL-10 secreted by the Th2
cell is responsible for the block in SPI-6 induction. Seques-
tering IL-10 with a blocking antibody almost completely
restored the capacity of Th1 cells to induce SPI-6 expres-
sion in the presence of Th2 cells (Fig. 4 d). Moreover, ex-
ogenously added recombinant IL-10 partially prevented
anti-CD40 as well as Th1-induced SPI-6 expression (Fig. 4
e). Our data indicate that IL-10 is critically involved in the
repression of SPI-6 induction by Th2 cells, but also suggest
that IL-10 is not the sole factor responsible for this repres-
sion. In agreement with this notion, sequestering IL-10 was
not sufficient to allow significant SPI-6 induction in the D1
cells upon incubation with Th2 cells (Fig. 4 e). Since Th2
cells are also known to produce IL-4, whereas Th1 cells se-
crete IFN-
 
 
 
 (29), we tested the involvement of these addi-
tional cytokines in Th-mediated regulation of SPI-6 ex-
pression. Our data reveal that only the combination of
blocking antibodies to IL-10 and IL-4 together with exog-
enously added IFN-
 
 
 
 could enable induction of SPI-6 by
Th2 cells (Fig. 4 e). Taken together, this suggests that the
differential induction of SPI-6 by Th1 and Th2 cells is due
to the overall cytokine profile of these T cell subsets in
combination with the expression of CD40L (Fig. 4 c).
Importantly, Th2-matured D1 were rapidly killed upon
incubation with CTLs (Fig. 4 f). This indicates that matu-
ration without SPI-6 induction results in a sensitive phe-
notype. In contrast, Th1-induced maturation did result in
SPI-6 expression as well as in resistance to CTL-induced
apoptosis (Fig. 4 f). Therefore, our data reveal a second
prominent difference, in addition to IL-12 secretion, in
the way Th1 and Th2 cells modulate DC function. This
coordinate regulation of SPI-6 and IL-12 expression is in
agreement with the notion that both play a role in Th1/
CTL-dependent immunity. Moreover, the differential ef-
fect of Th1 and Th2 on SPI-6 expression indicates that
CTL resistance is not necessarily linked to DC maturation,
which was also apparent from the fact that immature SPI-6
gene-transduced D1 cells are highly resistant to CTL kill-
ing (Fig
 
.
 
 3 f).
 
Exhausted DCs Maintain High Levels of SPI-6/PI-9.
 
SPI-6–mediated resistance of mature DCs to CTL-induced
killing is expected to positively affect the life span of DCs,
whereas the induction of T cell memory was reported to
require persistence of these APCs (46, 47). Newly matured
DCs were shown to efficiently drive activation of polarized
effector T cells, which involves secretion of IL-12. At later
time points, the same DCs become “exhausted,” lose pro-
duction of IL-12 and preferentially prime nonpolarized
memory-type T cells (47). In view of these findings one
would predict that efficient induction of T cell memory re-
quires survival of exhausted DCs. Since we have observed
that DCs protection is mediated by high expression of SPI-
6/PI-9, we investigated the expression levels of this inhibi-
tor of DC death in newly matured versus exhausted DCs.
 
In accordance with the results reported by Langekamp et
al. (47), we found that human monocyte–derived DCs
treated with LPS for 6 h, but not those treated for 24 or
48 h, secrete IL-12 upon a secondary stimulation with CD40L
(Fig. 5 a). This confirms the exhausted nature of DCs
treated for longer periods of time with LPS. However,
treatment of these exhausted DCs with CD40L did result
in increased maturation as determined by B7-2 expression
(Fig. 5 b), indicating that these DCs are responsive to a sec-
ondary stimulus, but are exhausted in terms of IL-12 secre-
tion. Importantly, when analyzing the expression of PI-9
we found that it was rapidly induced and remained high for
at least 48 h upon CD40L or LPS treatment (Fig. 5 c). This
indicates that PI-9 is expressed in both newly matured and
exhausted human DCs and implies that mature DCs are
protected from CTL-induced apoptosis even when in an
exhausted state.
We found that this feature is conserved between
mouse and man as LPS treatment of D1 cells strongly,
but transiently induced the secretion of IL-12p40. Secre-
tion was mainly observed during the first 24 h and de-
creased significantly afterwards (Fig. 5 d), whereas matu-
ration as measured by B7-2 expression increased in time
(Fig. 2 b). Anti-CD40–induced IL-12p40 secretion by
D1 was less pronounced, but also transient (Fig. 5 d).
Similar results were obtained using primary bone marrow
DCs (data not shown). This indicates that also murine
DCs reach a state of exhaustion when considering IL-12
secretion. Nevertheless, SPI-6 expression steadily in-
creased up to 72 h after the addition of LPS or anti-
CD40 and remained high for at least another 24 h (Fig. 5
e). Taken together, our data argue for a role for SPI-6/
PI-9 in the protection of DCs against CTL-induced
apoptosis and suggest that SPI-6/PI-9–mediated DC sur-
vival may be of particular importance for the induction
of proper T cell memory.
 
Discussion
 
We have shown that expression of the serpin SPI-6/PI-9
in DCs is upregulated upon DC activation by LPS treat-
ment, CD40 triggering, or Th1 cells. Expression of SPI-6/
PI-9 is tightly linked to resistance of DCs to CTL-induced
apoptosis. The causal connection between SPI-6 overex-
pression and resistance to CTL-mediated apoptosis is illus-
trated particularly well by the fact that retroviral transduc-
tion of DCs with the SPI-6 gene, although not affecting the
immature state of the cells, does elicit resistance to killing.
In a parallel study involving immunohistochemical staining
of human lymphoid organs, we found expression of PI-9 in
DCs (35). Our present work reveals that expression of SPI-
6/PI-9 is dependent on the maturation status and shows
that it is of functional significance to DC survival.
The need for DCs to protect themselves from CTL-
mediated eradication can be deduced from three studies
that have demonstrated CTL-dependent clearance of injected
DCs in mice (B. Ludewig, University of Zurich, personal
communication; references 24 and 25). Monitoring of pri- 
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mary murine DC populations after reinjection into synge-
neic mice revealed that at least a fraction of these DCs mi-
grated to the lymph nodes, but also that these DCs were
subsequently cleared from the lymph nodes in a CTL-
dependent fashion. In one of these studies a role for per-
forin in DC clearance was postulated (24), whereas in a
second study this process was shown to be independent of
perforin (B. Ludewig, University of Zurich, personal com-
munication). Importantly, in neither of these studies the
maturation status of the DCs was determined. Therefore,
we interpret these studies as a demonstration that DCs can
indeed serve as targets for CTLs in vivo, without pinpoint-
ing the CTL effector mechanisms involved in relation to
the DC maturation status.
The mechanism by which we find DCs to protect them-
selves from CTL-mediated apoptosis is also exploited for
immune escape by certain viruses. Orthopoxviruses, in par-
ticular cowpox, rabbitpox, and vaccinia virus, use serpins to
protect themselves from the host’s immune response (48).
One of these poxvirus serpins, SPI-2 (CrmA), was shown
to target GrB as well as caspases (49). In agreement with
our observations that SPI-6 can prevent cytotoxicity, SPI-2
in combination with SPI-1, can protect cells from alloreac-
tive CTL-induced killing via both perforin and death re-
ceptor-dependent pathways in vitro
 
 
 
(48). More impor-
tantly, rabbit poxvirus lacking either or both of the serpins
are much less virulent as compared with the normal virus
(48). This indicates that expression of GrB-inhibitory ser-
pins can prevent CTL-induced killing not only in vitro
 
 
 
but
also in vivo.
Of significance with respect to the in vivo relevance of
 
our observations is also the fact that we have used DNA
fragmentation, a measure for apoptosis, as a read-out for
cytotoxicity, rather than the chromium release assay. Re-
cent experiments have revealed that this so called JAM as-
say more closely reflects the in vivo situation (9). In this
particular study it was reported that cells lacking the man-
nose-6-phosphate receptor, which binds GrB and is es-
sential for entry of GrB into the target cell, resist
CTL-induced killing in vitro as measured by DNA frag-
mentation, while their receptor-transfected counterparts
were fully CTL sensitive. However, both lines were equally
sensitive to the actions of the CTLs in vitro when measured
with a classical chromium-release assay. Grafting of these
cells into mice revealed that the GrB receptor–deficient
cells survive in vivo, despite massive infiltration of CTLs,
which do eradicate the receptor-positive line (9). This work
convincingly demonstrates that the in vitro
 
 
 
chromium re-
lease overestimates the capacity of CTLs to lyse in vivo. In
line with these observations, we have previously shown
that the DNA fragmentation assay provides a better insight
into the in vivo CTL-dependent cytotoxicity towards tumor
cells than the classical chromium release assay (32). The ef-
fect of SPI-6 described here is most prominent when using
apoptosis as a read-out, although it is detectable when
CTL-induced chromium release is tested. However, this
release is only marginally reduced upon maturation of D1 cells
(data not shown). Nevertheless, others have shown that PI-9
(the human SPI-6) is capable of preventing chromium re-
lease to a reasonable extent when LAK cells are used as ef-
fector population (50). Apparently, SPI-6 can prevent DC
lysis in vitro as well when tested under limiting conditions.
Figure 5. SPI-6/PI-9 is highly
expressed in exhausted DCs. Pri-
mary human monocyte–derived
DCs were treated for the indicated
times with 100 ng/ml LPS after
which the medium was refreshed.
After a secondary incubation for
24 h in the absence (light gray) or
presence (dark gray) of Lz-CD40L at
1  g/ml, (a) IL12p70 secretion was
analyzed by ELISA and (b) B7-2 ex-
pression was analyzed by FACS®. (c)
In addition, PI-9 expression was de-
termined at the indicated times after
either LPS or Lz-CD40L treatment
of human DCs. D1 cells were
treated for different periods of time
with LPS or FGK45 as indicated. (d)
IL-12p40 secretion by the D1 cells
was determined by ELISA. To ana-
lyze the IL-12 production in the fi-
nal 24 h of incubation, the culture
medium was refreshed for the last
24 h. (e) SPI-6 expression was deter-
mined in parallel by Western blot
analysis. Lysates from equal numbers
of cells were applied on SDS-PAGE
(0.5   106 cells) and equal protein
loading was checked by ponceau S
staining and control Western blot
analysis for MAPK (bottom).665 Medema et al.
However, the effect is clearly more prominent when apop-
tosis is taken as a readout, which as discussed more closely
correlates to the in vivo sensitivity of the target cells.
It is important to note that, in addition to SPI-6/PI-9
overexpression, several other antiapoptotic mechanisms
were found to increase the life span of DCs. For instance,
both immature and LPS- or CD40-matured DCs are resis-
tant to death receptor-induced death, which is achieved by
the expression of the antiapoptotic protein cellular Fas-asso-
ciated death domain–like IL-1 –converting enzyme (FLICE)
inhibitory protein (c-FLIP; references 51 and 52). We have
confirmed these observations for the D1 cell line (data not
shown). As c-FLIP cannot prevent perforin-dependent
killing (32, 53), it cannot be responsible for the observed
inhibition of cytotoxicity in mature DCs as reported here
(Fig. 1). Instead, c-FLIP appears to serve as a more general
survival mechanism that not only protects DCs from death
receptor-dependent apoptosis by CTLs, but also by
CD95L-positive Th cells. In agreement, recent evidence
indicates that CD95 cross-linking on DCs during cognate
interaction with Th cells triggers DC maturation rather
than death (54).
The predominant Th-derived maturation signal, deliv-
ered to the CD40 receptor on DCs, was also found to pro-
mote DC survival. This involves upregulation of Bcl-2
(55), a general regulator of apoptosis that prevents mito-
chondrial-dependent death induced by a variety of cellular
stress signals (56). A third Th cell–derived signal for DCs
involves TNF-related activation-induced cytokine expres-
sion (TRANCE), a member of the TNF superfamily that
also promotes survival. It results in induction of the Bcl-2
homologue Bcl–XL (57), which protects DCs in a similar
fashion as Bcl-2. Thus, DCs receive a mixture of signals
that protect them against apoptosis. Importantly, unlike the
antiapoptotic pathways represented by c-FLIP and Bcl-2/
Bcl-XL, overexpression of SPI-6/PI-9 is not a general sur-
vival mechanism. Rather, it selectively offers protection of
mature DCs against the actions of GrB and thereby allows
DCs to survive in the hostile vicinity of activated CTLs. As
such, it may be of particular relevance in the prevention of
a premature decline in CTL immunity.
A prominent aspect of our findings is the differential reg-
ulation of SPI-6 expression in DCs by Th1 versus Th2
cells. The failure of Th2 cells to upregulate SPI-6, as well as
their dominant inhibitory effect on Th1-induced SPI-6 ex-
pression, depends on the secretion of the immunoregula-
tory cytokine IL-10 (Fig. 4). It is tempting to speculate that
this Th2/IL-10–mediated effect may result in a more rapid
turnover of mature DCs in the T cell rich areas of the pe-
ripheral lymphoid organs and, thereby, favor skewing to-
wards humoral responses. Importantly, the SPI-6/PI-9–
dependent protection induced by Th1 cells (CD40) or LPS
persists for a long period of time and recent evidence sug-
gests that prolonged DC survival is required for the induc-
tion of T cell memory. At later timepoints after the induc-
tion of maturation DCs become exhausted and induce
CCR7  nonpolarized T cells. These T cells act as “central
memory” cells (23), i.e., T cells without apparent effector
function but with the capacity to home to the lymphoid
organs. Our data strongly argue that SPI-6/PI-9 is involved
in extending the life span of a DCs in the face of a CTL re-
sponse. Therefore, SPI-6/PI-9 constitutes a novel func-
tional marker for DCs, the expression of which coincides
with LPS, anti-CD40, and Th1-induced DC maturation.
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